Plasmodium DDI1 is a potential therapeutic target and important chromatin-associated protein.

[Display omitted] • Plasmodium DDI1 protein is expressed in all major life cycle stages and is crucial for parasite development. • Infection of mice with DDI1 knock-down parasites confers immunity to subsequent infection. • Plasmodium DDI1 is associated with chromatin and DNA-protein crosslinks. • DDI1 knock-down parasites show enhanced susceptibility to HIV protease inhibitor lopinavir and antimalarial artemisinin. • Plasmodium DDI1 could be a therapeutic target for malaria control. DNA damage inducible 1 protein (DDI1) is involved in a variety of cellular processes including proteasomal degradation of specific proteins. All DDI1 proteins contain a ubiquitin-like (UBL) domain and a retroviral protease (RVP) domain. Some DDI1 proteins also contain a ubiquitin-associated (UBA) domain. The three domains confer distinct activities to DDI1 proteins. The presence of a RVP domain makes DDI1 a potential target of HIV protease inhibitors, which also block the development of malaria parasites. Hence, we investigated the DDI1 of malaria parasites to identify its roles during parasite development and potential as a therapeutic target. DDI1 proteins of Plasmodium and other apicomplexan parasites share the UBL-RVP domain architecture, and some also contain the UBA domain. Plasmodium DDI1 is expressed across all the major life cycle stages and is important for parasite survival, as conditional depletion of DDI1 protein in the mouse malaria parasite Plasmodium berghei and the human malaria parasite Plasmodium falciparum compromised parasite development. Infection of mice with DDI1 knock-down P. berghei was self-limiting and protected the recovered mice from subsequent infection with homologous as well as heterologous parasites, indicating the potential of DDI1 knock-down parasites as a whole organism vaccine. Plasmodium falciparum DDI1 (Pf DDI1) is associated with chromatin and DNA-protein crosslinks. Pf DDI1-depleted parasites accumulated DNA-protein crosslinks and showed enhanced susceptibility to DNA-damaging chemicals, indicating a role of Pf DDI1 in removal of DNA-protein crosslinks. Knock-down of Pf DDI1 increased susceptibility to the retroviral protease inhibitor lopinavir and antimalarial artemisinin, which suggests that simultaneous inhibition of DDI1 could potentiate antimalarial activity of these drugs. As DDI1 knock-down parasites confer protective immunity and it could be a target of HIV protease inhibitors, Plasmodium DDI1 is a potential therapeutic target for malaria control. [ABSTRACT FROM AUTHOR]